Kiora Pharmaceuticals Inc 1Q 2026: Revenue ($2.4M), Net income ($2.42M), EPS ($0.58) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Kiora Pharmaceuticals Inc reported its Q1 2026 results, showing a comprehensive loss of $2.4M and a net loss of $2.42M, with a diluted EPS of $0.58. This reflects a year-over-year increase in losses. The company executed a global license for KIO-301, received $16M upfront, and initiated Phase 2 trials for its pipeline products. R&D expenses are largely reimbursed, with cash runway projected into late 2028.
Kiora Pharmaceuticals Inc reported results for the first quarter of fiscal 2026, posting a comprehensive loss of ($2.4M) and a net loss of ($2.42M), or diluted loss per share of ($0.58), compared with losses of ($2.21M), ($2.19M) and ($0.52) respectively in the prior-year quarter.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | ($2.4M) | ($2.21M) | (8.7%) |
| Net income² | ($2.42M) | ($2.19M) | (10.3%) |
| Diluted EPS³ | ($0.58) | ($0.52) | (11.5%) |
¹ Reported as “Comprehensive Loss”. ² Reported as “Net Loss”. ³ Reported as “Loss per Common Share - Diluted”.
Business Highlights
- Partnership & licensing: Executed an exclusive global license (ex-Asia) for KIO-301 with Théa Open Innovation, including $16M upfront plus potential milestones and royalties.
- Clinical progress: Completed Phase 1b ABACUS-1 with positive topline and full data; Phase 2 ABACUS-2 initiated in 2025 with dosing underway.
- Asian expansion option: Granted Senju an exclusive option for key Asian territories for KIO-301 with a $1.25M nonrefundable option fee and up to $109.5M plus royalties if exercised.
- Pipeline: Advanced KIO-104 into Phase 2 for retinal inflammation; KIO-101 is paused and available for partnership.
- Funding outlook: R&D expenses for KIO-301 are largely reimbursed by the partner, with cash runway projected into late 2028 to support planned operations.
Original SEC Filing: KIORA PHARMACEUTICALS INC [ KPRX ] - 10-Q - May. 08, 2026